Heart Patients May Indicate a Risk of Liver Disease After Fontan Surgery

Heart patients who undergo Fontan surgery are at a risk of developing liver disease, reveals study.

Fontan operation is a surgical procedure for a complex congenital heart defect in children. Patients who undergo the Fontan surgery are at a risk of developing progressive liver fibrosis, this could be a buildup of fibrous deposits, that occur as a result of the circulation that is created by the surgery, finds a new study.//

The research team from Children’s Hospital of Philadelphia said that the findings may underscore the importance of improving the ongoing medical surveillance. This could also make the physicians develop the most appropriate care for the patients.

Pediatric Heart Surgery can be Enhanced by Addition of New Tool
A way to simulate blood flow on the computer to optimize surgical designs has been developed by a team of researchers at the University of California, San Diego and Stanford University.

‘Risk of progressive liver fibrosis may develop in heart patients who undergo the Fontan surgery.’

The Fontan operation is a series of three staged reconstructive surgeries in children born with single-ventricle disease, a life-threatening condition characterized by a severely underdeveloped ventricle, one of the heart's two pumping chambers. The palliative surgeries re-route blood to the lungs, but result in an abnormal physiology that puts many organ systems at risk.

One such organ is the liver, in which fibrosis develops in response to elevated pressure within the veins. Over time this can lead to liver cirrhosis, a condition of significant liver impairment.

"We have known for some time that liver fibrosis is a complication of Fontan surgery, but this was an important study that demonstrated that the length of time after the Fontan operation is a significant contributor to the degree of fibrosis," said study leader David J. Goldberg, MD, a pediatric cardiologist at Children's Hospital of Philadelphia (CHOP).

Non-Alcoholic Fatty Liver Disease may Increase Heart Disease
A patient suffering from fatty liver disease is prone to an increased risk of heart disease as well as the mortality rates associated with it, a new study has found.

Goldberg and colleagues published their study online April 26 in the Journal of the American Heart Association.

The research is a retrospective analysis of 67 children and adolescents (with a mean age of 17 years) evaluated at CHOP between 2009 and 2014 under the hospital's Single Ventricle Survivorship Program. Most of these patients were evaluated 10 to 15 years after their original Fontan operation.

Fatty Liver Disease: A Growing Health Problem in India - Causes, Symptoms, Diagnosis, Treatment
Non alcoholic fatty liver disease (NAFLD) is the leading cause of liver dysfunction worldwide and is a rapidly growing health problem in India.

Most of the patients had no overt symptoms of liver disease, which progresses very gradually, and were generally considered to be in good health. All 67 patients showed evidence of some liver fibrosis, measured by the quantity of collagen deposits found after needle biopsies of the patients' livers. The only risk factor the researchers found was time from Fontan--the degree of fibrosis increases over time. The researchers added that there are likely other risk factors for fibrosis not measured in their analysis.

"Our finding that liver fibrosis is universal after the Fontan operation reinforces the need for ongoing surveillance of the liver in this patient population," said Goldberg.

Childhood Acquired Hepatitis C Virus Increases Risk Of Liver Disease
Patients with perinatal exposure to HCV developed cirrhosis at an earlier age and are at the risk of liver-related death.

"However, it is important to find a less invasive method than liver biopsy to measure liver fibrosis, as well as to investigate possible medications that may reduce the rate of fibrosis. As we work to develop clinical guidelines for liver surveillance, we can better provide care tailored to our individual patients."

Source-Eurekalert